OFATUMUMAB (KESIMPTA) prior authorization at EmblemHealth
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
EmblemHealth reviews OFATUMUMAB (KESIMPTA) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody [EPC]. The FDA-approved indication (2009) is SOLUTION. EmblemHealth-specific context: NY-based; operates HIP (HMO) and GHI (PPO) brands; ~3M members. Administers the NYC municipal employee GHI-CBP plan — high-volume source of OON disputes for retirees. NY DFS oversight; ConnectiCare is the Connecticut subsidiary.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- EmblemHealth's medical policy URL referenced in the cover letter
EmblemHealth's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- HIP HMO referral denials
- GHI PPO out-of-network reductions (NYC municipal employee plan)
- Behavioral health prior auth
- Specialty drug PA
If the PA is denied
EmblemHealth gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.emblemhealth.com/providers) with the same packet plus a peer-reviewed citation supporting OFATUMUMAB (KESIMPTA)for the patient's indication.
Contact EmblemHealth
- Provider portal: https://www.emblemhealth.com/providers
Frequently asked questions
What documentation does EmblemHealth need for OFATUMUMAB (KESIMPTA) prior auth?
EmblemHealth's typical PA packet for OFATUMUMAB (KESIMPTA): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at EmblemHealth?
Standard OFATUMUMAB (KESIMPTA) PA decisions at EmblemHealth: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does EmblemHealth most often reject OFATUMUMAB (KESIMPTA) for?
Across EmblemHealth's book the common rejection patterns include: HIP HMO referral denials; GHI PPO out-of-network reductions (NYC municipal employee plan); Behavioral health prior auth. For OFATUMUMAB (KESIMPTA) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with EmblemHealth on OFATUMUMAB (KESIMPTA)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the OFATUMUMAB (KESIMPTA) PA packet
Open ApprovalHelp — generate a OFATUMUMAB (KESIMPTA) prior-auth packet tailored to EmblemHealth's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com